Correlation Between Merck and Acrivon Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Merck and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Merck and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Merck Company and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on Merck and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Merck with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Merck and Acrivon Therapeutics,.

Diversification Opportunities for Merck and Acrivon Therapeutics,

0.19

Correlation Coefficient

Merck  Acrivon Therapeutics,

Average diversification

The 3 months correlation between Merck and Acrivon is 0.19. Overlapping area represents the amount of risk that can be diversified away by holding Merck Company and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and Merck is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Merck Company are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of Merck i.e., Merck and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between Merck and Acrivon Therapeutics,

Considering the 90-day investment horizon Merck Company is expected to generate 0.28 times more return on investment than Acrivon Therapeutics,. However, Merck Company is 3.57 times less risky than Acrivon Therapeutics,. It trades about -0.12 of its potential returns per unit of risk. Acrivon Therapeutics, Common is currently generating about -0.06 per unit of risk. If you would invest  10,890  in Merck Company on October 4, 2024 and sell it today you would lose (992.00) from holding Merck Company or give up 9.11% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Merck Company  vs.  Acrivon Therapeutics, Common

Merck Company

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Merck Company has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in February 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Merck and Acrivon Therapeutics,

The main advantage of trading using opposite Merck and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Merck position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.

The idea behind Merck Company and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.